Efficacy and safety assessment of neoadjuvant paclitaxel-based chemotherapy in Chinese triple negative breast cancer

Abstract

Objective To assess the efficacy and safety of neoadjuvant paclitexal-based chemotherapy in Chinese triple negative breast cancer. Methods Operable breast cancer patients with tumor size over 2 cm, ER negative, PgR negative, and Her-2 negative were enrolled. The included patients were randomized into 3 groups to receive 4 cycles neoadjuvant chemotherapy. Group A were treated with paclitaxel(175 mg/m2, D1) plus epirubicin (75mg/m2, D1) chemotherapy every 3 weeks; group B were treated with paclitaxel (175 mg/m2, D1) plus cisplatin(30 mg/m2, D1-D3) chemotherapy every 3 weeks; and group C were treated weekly with paclitaxel(175mg/m2, D1, D8,D15) plus cisplatin(30mg/m2, D1-D3) chemotherapy erery 4 weeks. The primary end point was primary tumor pathologic complete remission (tpCR) rate, and the secondary end point was overall response (OR) rate. Safety assessment was performed according to CTCAE v3.0. Results Thirty-one eligible patients were enrolled and randomized into 3 groups. All patients completed 4 cycles preoperative chemotherapy. In group A, tpCR rate was 30.0%, and OR rate was 90.0%, respectively. In group B, tpCR rate was 33.3%, and OR rate was 100.0%, respectively. In group C, tpCR rate was 83.3%, and OR rate was 91.7%, respectively. The tpCR rate of group C was much the other two groups' (P ＜ 0.05). No patient needed to reduce drug doses according to the Adverse Event. Conclusion Using weekly paclitexal plus cisplatin neoadjuvant chemotherapy to treat operable triple negative breast cancer patients has higher pCR rate, good tolerability, and safety. Key words: Triple negative breast cancer; Neoadjuvant chemotherapy; Paclitaxel